Paper36966849
A proteoglycan isolated from Ganoderma lucidum attenuates diabetic kidney disease by inhibiting oxidative stress-induced renal fibrosis both in vitro and in vivo.
Pan Y and 7 others. J Ethnopharmacol, 2023. Cited by 26 papers, by iCite.
Cite this record
ConductScience Library. A proteoglycan isolated from Ganoderma lucidum attenuates diabetic kidney disease by inhibiting oxidative stress-induced renal fibrosis both in vitro and in vivo. Papers, record 36966849. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36966849
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- A proteoglycan isolated from Ganoderma lucidum attenuates diabetic kidney disease by inhibiting oxidative stress-induced renal fibrosis both in vitro and in vivo.
- PubMed
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Diabetes Mellitus | Major topic |
| Diabetic Nephropathies | Major topic |
| Reishi | Major topic |
| Reactive Oxygen Species | |
| NF-kappa B | |
| Kidney | |
| Blood Glucose | |
| Antioxidants | |
| Mice | |
| Rats | |
| Proteoglycans | |
| Oxidative Stress | |
| Superoxide Dismutase | |
| Animals | |
| Fibrosis | |
| Urogenital Abnormalities |
Source PubMed
Cited by16
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 26 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42515691 | Hugan Tablets Alleviate Alcoholic Liver Injury by Modulating Hepatic Glutathione Metabolism and PPARγ/NRF2/GPX4-Related Antioxidant Defense. | Pharmaceuticals (Basel) | 2026 | https://conductscience.org/library/papers/42515691 | PubMed |
| 42511467 | Targeting CDK2 and AURKA with Cerevisterol from Ganoderma lucidum to Sensitize Colorectal Cancer to Chemotherapy. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42511467 | PubMed |
| 42188043 | Ganoderma lucidum as a Functional Bioactive Candidate for Glycemic Regulation: Mechanisms, Preclinical Evidence, and Clinical Translation. | Metabolites | 2026 | https://conductscience.org/library/papers/42188043 | PubMed |
| 42147328 | Mechanism of Ganoderma lucidum polysaccharides in the mangement of diabetes and its complications. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/42147328 | PubMed |
| 42076830 | Qiling Hushen Formula Ameliorates Type 2 Diabetic Kidney Disease via Gut-Kidney Axis Restoration and TLR4/NF-κB/NLRP3 Suppression. | J Diabetes Res | 2026 | https://conductscience.org/library/papers/42076830 | PubMed |
| 41731519 | ROS-responsive Ganoderma lucidum polysaccharide nanocomposite targeting prosenescent oxidative stress niche for structural and functional diabetic tendon regeneration. | J Nanobiotechnology | 2026 | https://conductscience.org/library/papers/41731519 | PubMed |
| 41048444 | Gut microbiota-derived short-chain fatty acids mediate the antifibrotic effects of traditional Chinese medicine in diabetic nephropathy. | Front Endocrinol (Lausanne) | 2025 | https://conductscience.org/library/papers/41048444 | PubMed |
| 40834279 | Overexpression of PON1 reduces high glucose induced renal tubular epithelial cell injury by activating PPARγ signaling pathway to alleviate diabetes nephropathy. | Arch Endocrinol Metab | 2025 | https://conductscience.org/library/papers/40834279 | PubMed |
| 40293615 | Modulation of renal fibrosis-related signaling pathways by traditional Chinese medicine: molecular mechanisms and experimental evidence. | Int Urol Nephrol | 2025 | https://conductscience.org/library/papers/40293615 | PubMed |
| 40291539 | Mechanistic Insights Into Ganoderma Lucidum for Diabetes Treatment via Network Pharmacology and Validation. | Diabetes Metab Syndr Obes | 2025 | https://conductscience.org/library/papers/40291539 | PubMed |
| 39465434 | Metabolic reprogramming and renal fibrosis: what role might Chinese medicine play? | Chin Med | 2024 | https://conductscience.org/library/papers/39465434 | PubMed |
| 39458524 | Renal Health Through Medicine-Food Homology: A Comprehensive Review of Botanical Micronutrients and Their Mechanisms. | Nutrients | 2024 | https://conductscience.org/library/papers/39458524 | PubMed |
| 38979022 | Yishen Jiangzhuo decoction attenuates cisplatin‑induced acute kidney injury by inhibiting inflammation, oxidative stress and apoptosis through the TNF signal pathway. | Exp Ther Med | 2024 | https://conductscience.org/library/papers/38979022 | PubMed |
| 38742197 | Lipid metabolism disorder in diabetic kidney disease. | Front Endocrinol (Lausanne) | 2024 | https://conductscience.org/library/papers/38742197 | PubMed |
| 38357745 | Study on effects and relevant mechanisms of Mudan granules on renal fibrosis in streptozotocin-induced diabetes rats. | Ren Fail | 2024 | https://conductscience.org/library/papers/38357745 | PubMed |
| 37553709 | Balancing adipocyte production and lipid metabolism to treat obesity-induced diabetes with a novel proteoglycan from Ganoderma lucidum. | Lipids Health Dis | 2023 | https://conductscience.org/library/papers/37553709 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| NFKB1 | 4790 | PubTator's text mining | https://conductscience.org/library/genes/4790 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36966849
GET https://conductscience.org/api/papers/v1/36966849/authors